Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tinengotinib + Fulvestrant in HR+/HER2- Advanced Breast Cancer
NCT07498478Phase 2Recruiting
- Sponsor
- TransThera Biosciences
- Start
- Mar 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tinengotinib in breast cancer, sponsored by TransThera Biosciences. Started Mar 2026; status: recruiting.
02
Drugs
tinengotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07498478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07498478.